Marta Soares

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10427440/publications.pdf

Version: 2024-02-01

567281 677142 1,133 24 15 22 h-index citations g-index papers 24 24 24 2320 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technology Assessment, 2015, 19, 1-504.	2.8	536
2	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. Health Technology Assessment, 2018, 22, 1-176.	2.8	70
3	Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technology Assessment, 2016, 20, 1-334.	2.8	62
4	Resolving the "Cost-Effective but Unaffordable―Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. Value in Health, 2018, 21, 266-275.	0.3	58
5	Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?. Value in Health, 2020, 23, 1613-1621.	0.3	57
6	Wounds research for patient benefit: a 5-year programme of research. Programme Grants for Applied Research, 2016, 4, 1-304.	1.0	50
7	Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regenerative Medicine, 2015, 10, 897-911.	1.7	41
8	A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. Value in Health, 2016, 19, 885-891.	0.3	38
9	Dilemmas in the interpretation of diagnostic accuracy studies on presurgical workup for epilepsy surgery. Epilepsia, 2012, 53, 1294-1302.	5.1	34
10	Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study. Health Technology Assessment, 2021, 25, 1-124.	2.8	29
11	Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. Clinical Genitourinary Cancer, 2020, 18, e418-e442.	1.9	28
12	Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties. Pharmacoeconomics, 2017, 35, 867-877.	3.3	22
13	Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-326.	2.8	21
14	Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. Value in Health, 2015, 18, 865-875.	0.3	17
15	The added clinical and economic value of diagnostic testing for epilepsy surgery. Epilepsy Research, 2014, 108, 775-781.	1.6	16
16	Negative pressure wound therapy versus usual care for Surgical Wounds Healing by Secondary Intention (SWHSI trial): study protocol for a randomised controlled pilot trial. Trials, 2016, 17, 535.	1.6	14
17	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation. Health Technology Assessment, 2020, 24, 1-248.	2.8	12
18	Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT. Health Technology Assessment, 2018, 22, 1-148.	2.8	10

#	Article	IF	CITATIONS
19	The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence. Pharmacoeconomics, 2016, 34, 901-912.	3.3	7
20	Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges. Pharmacoeconomics, 2022, , 1.	3.3	6
21	Critical appraisal of cost-effectiveness and cost-utility studies in health care. Evidence-based Nursing, 2008, 11, 99-102.	0.2	3
22	Economic evaluation of healthcare technologies using primary research. Evidence-based Nursing, 2008, 11, 67-71.	0.2	2
23	The costâ€effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa. Journal of the International AIDS Society, 2020, 23, e25469.	3.0	O
24	Cost-effectiveness of point-of-care creatinine testing to assess kidney function prior to contrast-enhanced computed tomography imaging. European Journal of Radiology, 2021, 142, 109872.	2.6	0